Therapeutic Area

Urea Cycle Disorder

Therapeutic area intelligence for Urea Cycle Disorder with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Teva →

Assets

FDA →

Recent signals(2)

RegulatoryJuly 4, 2026

FDA Grants Approval for Glycerol Phenylbutyrate ANDA219540

The FDA has granted approval for the ANDA219540 application for Glycerol Phenylbutyrate submitted by MSN.

RegulatoryJuly 3, 2026

Teva's Glycerol Phenylbutyrate ANDA218738 Receives AP Status from FDA

Teva Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Glycerol Phenylbutyrate.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Metabolic Disorders →

Urea Cycle Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.